Loading…
This event has ended. View the official site or create your own event → Check it out
This event has ended. Create your own
View analytic
Tuesday, March 5 • 1:00pm - 4:00pm
Future of Medicine - A Policy Basis for a New System LIMITED

Log in to save this to your schedule and see who's attending!

Limited Capacity seats available

Global health challenges, their related socio-economic implications and the future of medicine can only be efficiently addressed by international, inter-disciplinary collaboration.

The various topics of the plenary are structured in a manner to guide participants from future health challenges to possible solutions and required actions to address these challenges. Speakers are invited to present their view on the key issues described below.

Global health challenges and economic implications

What are the upcoming global health challenges and what are the economic implications of such challenges? Healthcare systems have no proper solutions in place to cope with these challenges and countries have no strategy how to finance healthcare under these expected developments. There is a need for new solutions.

50 year roadmap for the future of medicine

These new solutions may only be delivered by top level research and development. However several
paradigm shifts in the R&D and healthcare landscapes are required to occur: To change from a fragmented R&D landscape to multidisciplinary and international collaborative research: To take advantage of the “massive data” century; to change research focus from individual molecules to biological systems; to restructure medicine by establishing a mechanism/biological system-based disease taxonomy. This has several implications ranging from restructuring medicine from being a current organ-centered  to a future on common disease mechanisms based medicine, new strategies in drug development and prescription, new organization of healthcare providers, to developing new curricula for education and training. These changes will be reflected in the 50 year roadmap. For more information, please visit http://www.globalsciencecollaboration.org/global-challenges/health

Frameworks for international collaborative research: technical, ethical and legal challenges

In order to allow such paradigm shifts, particularly to enable interdisciplinary and international collaborative research common technical standards, and harmonized ethical and legal frameworks are essential. This will be elaborated on the example of “massive data” –driven healthcare addressing challenges of common taxonomies, quality management, technical challenges, data protection and
privacy.

Role of academia and industry in health innovation

The paradigm shifts in the R&D landscape will also affect the academia-industry relationship. There is a need for increased collaboration between academia and industry particularly in the pre-competitive field. This will also impact on role of patents and open access information. Several examples of R&D partnerships in the precompetitive field will be presented.

Towards a global health science policy

Basically all of the above highlighted issues are of global nature requiring global collaboration for an efficient response. Therefore, the question arises whether the time is ripe for an international concerted action to develop the solution that will allow to respond to future health challenges and to sustainably
finance healthcare systems.

 

AGENDA

 


Moderators
avatar for Clive Cookson

Clive Cookson

Science Editor, Financial Times
Clive Cookson has worked in science journalism for the whole of his professional life. He graduated in chemistry from Oxford University in 1974.  After journalism training on the Luton Evening Post, he became science correspondent of the Times Higher Education Supplement in London and then spent four years in Washington as American Editor of THES. He returned to London in 1981 as technology correspondent of the Times and moved to BBC... Read More →

Speakers
avatar for Peter Boyle

Peter Boyle

President of the International Prevention Research Institute, Lyon, France
Dr Boyle’s appointment as President of the International Prevention Research Institute, Lyon, France follows immediately on his tenure as Director of the International Agency for Research on Cancer (IARC/WHO) from 2004 to 2008 in Lyon, France. He previously had had a number of successive appointments with Glasgow University Department of Medicine, the West of Scotland Cancer Surveillance Unit, Harvard School of Public Health and the... Read More →
avatar for Prof. Hugh Brady

Prof. Hugh Brady

President of University College Dublin, Ireland
Dr Hugh Brady was educated at UCD where he was awarded degrees in Medicine (1982) and Science (1984). He was subsequently awarded PhD and MD degrees for research in renal physiology and molecular medicine. He was appointed President of UCD in January 2004. Since taking up his position as President, Hugh Brady has overseen and implemented a multipronged institutional change programme which included major curriculum reform at undergraduate and... Read More →
avatar for Dr Martha Brumfield

Dr Martha Brumfield

President and CEO Critical Path Institute
Martha Brumfield, Ph.D., was recently named the interim president and chief executive officer of the Critical Path Institute. In this role, Brumfield will lead the institute in its mission to foster development of new evaluation tools, which accelerate medical product approval. Brumfield assumes the role of CEO after most recently serving as Critical Path Institute's director of International & Regulatory Programs. In that position, she... Read More →
avatar for David Byrne

David Byrne

David Byrne was appointed EU Commissioner in 1999 and held the portfolio of Health and Consumer Affairs during the Prodi Commission, when he established the European Centre for Disease Control (ECDC) and the European Food Safety Authority (EFSA). Prior to that, he served as Attorney General in Ireland.  Following his period of office in the Commission, he was appointed as Special Envoy of the World Health Organisation (WHO) to give... Read More →
avatar for Prof. Peter Coveney

Prof. Peter Coveney

Director of the UCL Computational Life & Medical Sciences Network
Prof Coveney is Director of the UCL Computational Life & Medical Sciences Network. He holds a Chair in | Physical Chemistry, and is Director of the Centre for Computational Science, an Honorary Professor of Computer Science, and a member of CoMPLEX at UCL. He is also a founding member of the UK e-Infrastructure Leadership Council, a Medical Academy Nominated Expert on Data, Algorithms, and Modelling for the UK Prime Minister’s... Read More →
avatar for Dr. Jacques Demotes

Dr. Jacques Demotes

Professor of Cell Biology
Jacques Demotes-Mainard, MD-PhD-MBA, is Professor of Cell Biology, has a background in clinical | neurology and a research curriculum as a basic neuroscientist, then as chair of a clinical research centre. Since 2004, co-ordinates the European Clinical Research Infrastructure Network (ECRIN, www.ecrin.org), funded by the FP6, then FP7 as the ESFRI-roadmap European infrastructure for clinical trials. Since 2005 | advisor at the Biology and... Read More →
avatar for Rainer Fischer

Rainer Fischer

Senior Executive Director of the Fraunhofer Institute for Molecular Biology and Applied Ecology
Prof Fischer is Department Head of the Institute for Molecular Biotechnology (RWTH Aachen University, Germany, 60 employees) and Senior Executive Director of the Fraunhofer Institute for Molecular Biology and Applied Ecology (500 employees at five sites in Germany and two wholly-owned subsidiaries in the USA and Chile). His expertise covers many areas of molecular biology and biotechnology, focusing on protein engineering, molecular medicine... Read More →
avatar for Sir Peter Gluckman

Sir Peter Gluckman

Chief Science Advisor to the Prime Minister of New Zealand
Prof. Gluckman trained in paediatrics and endocrinology at the Universities of Otago, Auckland and the University of California, San Francisco. He returned to the University of Auckland 1980 to establish a research group in perinatal physiology and was executive Dean of the Faculty of Medicine and Health Sciences from 1992-2001 and from 2001-2009 was foundation director of the Liggins Institute of the University of Auckland where he now heads the... Read More →
avatar for Michel Goldman, MD, PhD

Michel Goldman, MD, PhD

Executive Director of IMI
Michel Goldman, Executive Director of IMI, builds and promotes networks of innovation, in close collaboration with all stakeholders involved in pharmaceutical R&D. IMI supports the launch and successful continuation of collaborative programmes to foster research and development activities on | more effective and safer therapies for patients across Europe. Michel Goldman is Professor of Immunology at the Faculty of Medicine of the... Read More →
avatar for Minister Gary Goodyear

Minister Gary Goodyear

Minister of State (Science and Technology), Government of Canada
Gary Goodyear was first elected to the Canadian House of Commons in 2004 to represent the riding of Cambridge, Ontario, and was re-elected in 2006 and 2008. On October 30, 2008, he was appointed Minister of State for Science and Technology, and on August 13, 2009, he was named Minister of State responsible for the Federal Economic Development Agency for Southern Ontario by Prime Minister Stephen Harper. Prior to entering federal politics, he... Read More →
avatar for Dr Esia Bushra Mohamed Hamid

Dr Esia Bushra Mohamed Hamid

Minsiter of Science and Communication, Sudan
Dr. Hamid was born in 1956 in Elmoglad, Sudan. He graduated as a medical doctor (physician) from the Faculty of Medicine, University of Khartoum, in 1982. He received his doctorate degree in the field of community medicine and higher diploma in business administration. | After a successful career in medicine he took extensive managerial roles in local governments as a minister of health, finance and economics at different states of Sudan since... Read More →
avatar for Dr. Tim Hubbard

Dr. Tim Hubbard

Wellcome Trust Sanger Institute
Tim Hubbard joined the Wellcome Trust Sanger Institute in 1997 and was one of the organisers of the sequencing of the human genome. In 1999 he co-founded the Ensembl project to analysis, organise and provided access to the human genome. Since then he has been responsible for groups identifying the full set of human genes and annotating their structures and is one of the leaders of the recently published ENCODE project. Prior to working on... Read More →
avatar for Dr. Richard Johnson

Dr. Richard Johnson

CEO, Global Helix LLC, Washington DC and National Academy of Sciences, Board on Life Sciences
CEO, Global Helix LLC, Washington DC and National Academy of Sciences, Board on Life Sciences | | Rick Johnson works at the intersection of the life sciences, Big Data, synthetic biology, healthy aging, neuroscience, and emerging platform technologies with collaborative research, impact capital investing and entrepreneurship, knowledge-based capital, public-private partnerships, and new innovation models for addressing global challenges... Read More →
avatar for Bartha Maria Knoppers

Bartha Maria Knoppers

Director of the Centre of Genomics and Policy, Faculty of Medicine, McGill University
Bartha Maria Knoppers, PhD (Comparative Medical Law), holds the Canada Research Chair in Law and Medicine (Tier 1: 2001 - ). She is Director of the Centre of Genomics and Policy, Faculty of Medicine, Department of Human Genetics, McGill University.  In 2007, she founded the international Population Project in Genomics and Society (P3G) and CARTaGENE Quebec’s population biobank (20,000 indiv.). Former holder of the Chair... Read More →
avatar for Dr. John C Lechleiter

Dr. John C Lechleiter

President and Chief Executive Officer of Eli Lilly and Company
John C. Lechleiter, Ph.D., has served as president and chief executive officer of Eli Lilly and Company since April 1, 2008.  He became chairman of the board of directors on January 1, 2009. Lechleiter joined Lilly in 1979 as a senior organic chemist in process research and development and became head of that department in 1982.  In 1984, he began serving as director of pharmaceutical product development for the Lilly Research Centre... Read More →
avatar for Hans Lehrach

Hans Lehrach

Hans Lehrach obtained his Ph.D. at the Max Planck Institute for Experimental Medicine and the Max Planck Institute for Biophysical Chemistry in 1974. Next he moved on to Harvard University, Boston (1974-1978) for a postdoc and then became group leader at EMBL, Heidelberg (1978-1987). He then moved to the Imperial Cancer Research Fund, London (1987-1994) to become head of the Genome Analysis Department. In 1994 he returned to Germany to become... Read More →
avatar for Prof Klaus Lindpaintner

Prof Klaus Lindpaintner

Vice President and Chief Scientific Officer at Thermo Fisher
Klaus Lindpaintner, MD, MPH, FACP is Vice President and Chief Scientific Officer at Thermo Fisher | Scientific, the world’s premier and largest company providing the scientific community and industry with highly innovative analytical instruments, reagents, and services. Previously, he held senior positions at F Hoffman-La Roche, where he spearheaded the company’s efforts in personalized health care and was | responsible for the... Read More →
avatar for Prof. Pauline Rudd

Prof. Pauline Rudd

Adjunct Professor of Glycobiology, University College Dublin
Professor Pauline M. Rudd BSc, LRIC, MA (Oxon), PhD is the Adjunct Professor of Glycobiology at University College, Dublin. She heads the GlycoSciences Research Group at the National Institute for BioProcessing Research and Training in Ireland (NIBRT). She has many links with pharmaceutical companies across the world because GlycoScience is a major area of specialised expertise required to ensure the safety and efficacy of biotherapeutic drugs... Read More →
avatar for Hans Westerhoff

Hans Westerhoff

Universities of Manchester and Amsterdam
Hans V. Westerhoff received his PhD from the University of Amsterdam. After a brief postdoc at the University of Padua he became Visiting Scientist at the National Institutes of Health (USA) to work on DNA supercoiling, regulation and control, and antimicrobial peptides.  After 6 years at the Netherlands Cancer Institute he became full professor of Microbial Physiology at the VU University Amsterdam.  From 2005 he also holds the... Read More →
avatar for Prof. John Wood

Prof. John Wood

Association of Commonwealth Universities
Professor John Wood CBE, FREng is the Secretary-General of the Association of Commonwealth Universities and visiting professor of materials at Imperial College London. Apart from academic appointments at the Open, Nottingham Universities and imperial College he was chief executive of the Council for the Central Laboratories of the Research Councils 2001-7 He was a founder member of the European Strategy Forum for Research Infrastructures and... Read More →
avatar for Kurt Zatloukal

Kurt Zatloukal

Professor of Pathology at the Medical University of Graz, Austria
Kurt Zatloukal, M.D. is professor of Pathology at the Medical University of Graz, Austria. He coordinated the preparatory phase of the European biobanking and biomolecular research infrastructure (BBMRI-ERIC) within the 7th EU framework programme. In this context it was crucial to establish Europe-wide harmonized processes and quality criteria that facilitate transnational research collaboration and are compliant with the requirements of latest... Read More →


Tuesday March 5, 2013 1:00pm - 4:00pm
European Parliament 4Q2